Phibro Animal Health Corporation (NASDAQ:PAHC) issued an update on its FY18 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $1.55-1.61 for the period, compared to the Thomson Reuters consensus estimate of $1.56. The company issued revenue guidance of $765-790 million, compared to the consensus revenue estimate of $780.13 million.
Phibro Animal Health Corporation (PAHC) opened at $35.75 on Wednesday. The firm has a market capitalization of $1,402.39, a PE ratio of 22.81, a P/E/G ratio of 4.09 and a beta of 1.35. Phibro Animal Health Corporation has a 12 month low of $26.10 and a 12 month high of $40.25. The company has a debt-to-equity ratio of 1.91, a current ratio of 3.26 and a quick ratio of 1.85.
Phibro Animal Health Corporation (NASDAQ:PAHC) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.01. Phibro Animal Health Corporation had a return on equity of 42.75% and a net margin of 8.87%. The firm had revenue of $193.40 million for the quarter, compared to analysts’ expectations of $189.89 million. During the same quarter last year, the business posted $0.36 EPS. Phibro Animal Health Corporation’s revenue was up 2.9% on a year-over-year basis. analysts expect that Phibro Animal Health Corporation will post 1.57 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 27th. Shareholders of record on Wednesday, December 6th will be given a dividend of $0.10 per share. The ex-dividend date of this dividend is Tuesday, December 5th. This represents a $0.40 dividend on an annualized basis and a yield of 1.12%. Phibro Animal Health Corporation’s payout ratio is presently 23.53%.
Several brokerages have recently issued reports on PAHC. Piper Jaffray Companies set a $41.00 price target on Phibro Animal Health Corporation and gave the company a buy rating in a report on Friday, October 6th. Zacks Investment Research lowered Phibro Animal Health Corporation from a buy rating to a hold rating in a report on Wednesday, November 1st. BidaskClub lowered Phibro Animal Health Corporation from a strong-buy rating to a buy rating in a report on Wednesday, August 23rd. Credit Suisse Group lifted their price target on Phibro Animal Health Corporation from $36.00 to $37.00 and gave the company an outperform rating in a report on Thursday, August 31st. Finally, ValuEngine lowered Phibro Animal Health Corporation from a buy rating to a hold rating in a report on Thursday, November 9th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of $38.25.
In other news, insider Dean J. Warras sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $35.70, for a total transaction of $357,000.00. Following the sale, the insider now directly owns 10,000 shares in the company, valued at $357,000. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Richard G. Johnson sold 29,807 shares of the business’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $35.66, for a total value of $1,062,917.62. Following the sale, the chief financial officer now owns 4,240 shares in the company, valued at $151,198.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 279,791 shares of company stock valued at $10,118,331. Corporate insiders own 51.88% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/22/phibro-animal-health-corporation-pahc-releases-fy18-earnings-guidance.html.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.
Receive News & Ratings for Phibro Animal Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.